Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Glucagon-like peptide-1(GLP-1) is secreted during a meal and increases glucose induced
insulin secretion. The enzyme dipeptidyl peptidase 4(DPP-4) cleaves intact GLP-1 within
minutes and DPP-4 inhibitors are therefore used for treatment of diabetic hyperglycemia. A
few animal studies have implicated the enzyme neutral endopeptidase 24.11 (24.11) in the
degradation of GLP-1 but if this is the case in humans with type 2 diabetes is unknown.
We therefore administered a NEP inhibitor, 194mg sacubitril, a DPP-4 inhibitor (sitagliptin
100mg the night before and 100mg 2 hours before), both, or placebo, to patients with type 2
diabetes during a standardized meal and measured plasma concentrations of GLP-1
Phase:
Phase 4
Details
Lead Sponsor:
University of Copenhagen
Collaborator:
Hvidovre University Hospital
Treatments:
Glucagon Glucagon-Like Peptide 1 LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Sitagliptin Phosphate Valsartan